Pfiz­er, Arv­inas’ breast can­cer drug com­bo keeps mo­men­tum af­ter Phase 1b up­date

Pfiz­er and Arv­inas’ tar­get­ed pro­tein de­grad­er plus Ibrance has shown promis­ing ef­fi­ca­cy in breast can­cer pa­tients in up­dat­ed da­ta from an ear­ly-stage tri­al, rais­ing an­tic­i­pa­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.